Biosensors are changing how we monitor health, but rapid innovation raises tough questions around privacy, regulation, and access. This article breaks down the key issues shaping their future.

AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) microarray. The MosaiQ ...